Nu Skin Enterprises Past Earnings Performance
Past criteria checks 0/6
Nu Skin Enterprises's earnings have been declining at an average annual rate of -40.9%, while the Personal Products industry saw earnings growing at 9.3% annually. Revenues have been declining at an average rate of 6.4% per year.
Key information
-40.9%
Earnings growth rate
-39.6%
EPS growth rate
| Personal Products Industry Growth | 20.9% |
| Revenue growth rate | -6.4% |
| Return on equity | -14.6% |
| Net Margin | -5.8% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Does Nu Skin Enterprises (NYSE:NUS) Have A Healthy Balance Sheet?
Nov 12
Nu Skin: New Products And Ongoing Digital Transformation Imply Undervaluation
Nov 12The Market Doesn't Like What It Sees From Nu Skin Enterprises, Inc.'s (NYSE:NUS) Revenues Yet As Shares Tumble 27%
Oct 04Nu Skin Enterprises' (NYSE:NUS) Returns On Capital Not Reflecting Well On The Business
Aug 31Insufficient Growth At Nu Skin Enterprises, Inc. (NYSE:NUS) Hampers Share Price
Aug 13Nu Skin Enterprises, Inc.'s (NYSE:NUS) CEO Might Not Expect Shareholders To Be So Generous This Year
May 30Is Nu Skin Enterprises (NYSE:NUS) Using Too Much Debt?
May 13Capital Allocation Trends At Nu Skin Enterprises (NYSE:NUS) Aren't Ideal
Mar 28Nu Skin: A Sell Signal Amidst Industry Decline And Strategic Uncertainty
Mar 04We Think You Can Look Beyond Nu Skin Enterprises' (NYSE:NUS) Lackluster Earnings
Feb 22Nu Skin Enterprises' (NYSE:NUS) Dividend Will Be Reduced To $0.06
Feb 19Analysts Just Shaved Their Nu Skin Enterprises, Inc. (NYSE:NUS) Forecasts Dramatically
Feb 18Nu Skin Enterprises, Inc. (NYSE:NUS) Could Be Riskier Than It Looks
Jan 18Nu Skin Enterprises (NYSE:NUS) Has A Somewhat Strained Balance Sheet
Dec 14Nu Skin Enterprises (NYSE:NUS) Has Affirmed Its Dividend Of $0.39
Nov 17Nu Skin: Is It Just A Growth Problem?
Oct 17Nu Skin Enterprises (NYSE:NUS) Could Be At Risk Of Shrinking As A Company
Oct 09When Should You Buy Nu Skin Enterprises, Inc. (NYSE:NUS)?
Sep 27Nu Skin: Attractive Valuation Trumps Near-Term Risks
Sep 12Nu Skin Enterprises (NYSE:NUS) Takes On Some Risk With Its Use Of Debt
Sep 08Nu Skin Enterprises (NYSE:NUS) Has Announced A Dividend Of $0.39
Aug 05Is Nu Skin Enterprises, Inc. (NYSE:NUS) Expensive For A Reason? A Look At Its Intrinsic Value
Jul 31Nu Skin: A High-Risk/High-Reward Turnaround Play Worth The Risks
Jun 26Is Now The Time To Look At Buying Nu Skin Enterprises, Inc. (NYSE:NUS)?
Jun 23We Think Nu Skin Enterprises (NYSE:NUS) Is Taking Some Risk With Its Debt
May 22Nu Skin Enterprises (NYSE:NUS) Will Pay A Dividend Of $0.39
May 07Nu Skin Enterprises (NYSE:NUS) Could Be Struggling To Allocate Capital
Apr 26Why Nu Skin Enterprises, Inc. (NYSE:NUS) Could Be Worth Watching
Mar 18Nu Skin Enterprises (NYSE:NUS) Will Pay A Larger Dividend Than Last Year At $0.39
Feb 19Revenue & Expenses Breakdown
How Nu Skin Enterprises makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 1,775 | -103 | 1,171 | 0 |
| 30 Jun 24 | 1,844 | -148 | 1,206 | 0 |
| 31 Mar 24 | 1,905 | -3 | 1,245 | 0 |
| 31 Dec 23 | 1,969 | 9 | 1,289 | 0 |
| 30 Sep 23 | 2,003 | 59 | 1,292 | 0 |
| 30 Jun 23 | 2,042 | 70 | 1,327 | 0 |
| 31 Mar 23 | 2,102 | 77 | 1,366 | 0 |
| 31 Dec 22 | 2,226 | 105 | 1,435 | 0 |
| 30 Sep 22 | 2,377 | 38 | 1,534 | 0 |
| 30 Jun 22 | 2,480 | 113 | 1,597 | 0 |
| 31 Mar 22 | 2,624 | 139 | 1,682 | 0 |
| 31 Dec 21 | 2,696 | 147 | 1,735 | 0 |
| 30 Sep 21 | 2,770 | 230 | 1,772 | 0 |
| 30 Jun 21 | 2,833 | 237 | 1,801 | 0 |
| 31 Mar 21 | 2,741 | 219 | 1,754 | 0 |
| 31 Dec 20 | 2,582 | 191 | 1,666 | 0 |
| 30 Sep 20 | 2,417 | 158 | 1,590 | 0 |
| 30 Jun 20 | 2,304 | 146 | 1,524 | 0 |
| 31 Mar 20 | 2,315 | 150 | 1,519 | 0 |
| 31 Dec 19 | 2,420 | 174 | 1,572 | 0 |
| 30 Sep 19 | 2,520 | 116 | 1,616 | 0 |
| 30 Jun 19 | 2,606 | 125 | 1,673 | 0 |
| 31 Mar 19 | 2,686 | 129 | 1,731 | 0 |
| 31 Dec 18 | 2,679 | 122 | 1,733 | 0 |
| 30 Sep 18 | 2,662 | 158 | 1,720 | 0 |
| 30 Jun 18 | 2,550 | 146 | 1,661 | 0 |
| 31 Mar 18 | 2,396 | 137 | 1,572 | 0 |
| 31 Dec 17 | 2,279 | 129 | 1,503 | 0 |
| 30 Sep 17 | 2,144 | 149 | 1,446 | 0 |
| 30 Jun 17 | 2,185 | 165 | 1,463 | 0 |
| 31 Mar 17 | 2,235 | 167 | 1,492 | 0 |
| 31 Dec 16 | 2,208 | 143 | 1,476 | 0 |
| 30 Sep 16 | 2,249 | 141 | 1,503 | 0 |
| 30 Jun 16 | 2,216 | 100 | 1,483 | 0 |
| 31 Mar 16 | 2,176 | 100 | 1,469 | 0 |
| 31 Dec 15 | 2,247 | 133 | 1,513 | 0 |
| 30 Sep 15 | 2,284 | 144 | 1,536 | 0 |
| 30 Jun 15 | 2,352 | 196 | 1,584 | 0 |
| 31 Mar 15 | 2,442 | 171 | 1,645 | 0 |
| 31 Dec 14 | 2,569 | 189 | 1,739 | 0 |
| 30 Sep 14 | 3,016 | 268 | 2,030 | 0 |
| 30 Jun 14 | 3,285 | 311 | 2,205 | 0 |
| 31 Mar 14 | 3,306 | 365 | 2,211 | 0 |
| 31 Dec 13 | 3,177 | 365 | 2,117 | 0 |
Quality Earnings: NUS is currently unprofitable.
Growing Profit Margin: NUS is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: NUS is unprofitable, and losses have increased over the past 5 years at a rate of 40.9% per year.
Accelerating Growth: Unable to compare NUS's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: NUS is unprofitable, making it difficult to compare its past year earnings growth to the Personal Products industry (-5.2%).
Return on Equity
High ROE: NUS has a negative Return on Equity (-14.6%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/20 23:18 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Nu Skin Enterprises, Inc. is covered by 15 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Anand Vankawala | Avondale Partners |
| Olivia Tong Cheang | BofA Global Research |
| April Scee | BTIG |